Embarking on a weight loss journey is a significant step towards improving your overall health and well-being
When analysed as maintenance of prior weight reduction, participants maintained an estimated 74.7% of previous weight reduction after tirzepatide and 79.3% after semaglutide with orforglipron compared with 49.2% and 37.6% with placebo
Jagielski D.: These were the top-selling GLP-1 drugs last quarter from Eli Lilly and Novo Nordisk
It continues to be evaluated across multiple areas of peptide and cellular research
The fundamental difference lies in retatrutide's broader receptor engagement approach, potentially offering enhanced metabolic benefits through simultaneous glucagon suppression and dual incretin hormone activation
Red flags include: no third-party COA available on request, COA issued by the same company selling the product, no mass spec data, dose listed only as a proprietary blend, and price far below market rate for verified peptide raw material